Unlike statin-induced myopathy, which involves direct myotoxicity and mitochondrial dysfunction (8), myosin inhibitors act through allosteric modulation of β-cardiac myosin, altering cross-bridge cycling without directly affecting skeletal muscle metabolism (9). The gene discussed is MYH14; the disease is myopathy.